Pre-made Inebilizumab benchmark antibody ( Whole mAb, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-273
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-Bios-ab-273 Category Tag

Product Details

Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults.

Products Name (INN Index)

Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody

INN Name

Inebilizumab

Target

CD19

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2015

Companies

Cellective Therapeutics,MedImmune

Conditions Approved

Neuromyelitis optica

Conditions Active

Autoimmune disorders,Myasthenia gravis,Renal transplant rejection

Conditions Discontinued

B-cell lymphoma,Chronic lymphocytic leukaemia,Diffuse large B-cell lymphoma,Follicular lymphoma,Multiple myeloma,Multiple sclerosis,Systemic scleroderma

Development Tech

POTELLIGENT Technology

Previous Name

NA

Gm Offical Target Name

CD19

Package

, ,

Genemeidi Omicron Variant Products
test
Previous
Next
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.